X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
female (64) 64
humans (63) 63
aged (59) 59
middle aged (59) 59
oncology (58) 58
adult (56) 56
index medicus (40) 40
breast cancer (36) 36
chemotherapy (32) 32
cancer (27) 27
male (27) 27
aged, 80 and over (26) 26
breast neoplasms - drug therapy (26) 26
prognosis (26) 26
antineoplastic combined chemotherapy protocols - therapeutic use (24) 24
treatment outcome (21) 21
immunohistochemistry (20) 20
research (20) 20
antineoplastic combined chemotherapy protocols - adverse effects (18) 18
breast neoplasms - pathology (18) 18
young adult (17) 17
disease-free survival (16) 16
paclitaxel (16) 16
research article (16) 16
survival (16) 16
chemotherapy, adjuvant (15) 15
colorectal cancer (15) 15
medicine (15) 15
epirubicin (14) 14
kaplan-meier estimate (13) 13
paclitaxel - administration & dosage (13) 13
retrospective studies (13) 13
therapy (13) 13
antineoplastic agents - therapeutic use (12) 12
neoplasm staging (12) 12
trastuzumab (12) 12
adjuvant chemotherapy (11) 11
breast neoplasms - mortality (11) 11
care and treatment (11) 11
clinical trials (11) 11
docetaxel (11) 11
protein expression (11) 11
randomized phase-iii (11) 11
analysis (10) 10
cancer research (10) 10
carcinoma (10) 10
colorectal neoplasms - drug therapy (10) 10
fluorouracil (10) 10
fluorouracil - administration & dosage (10) 10
gene expression (10) 10
metastasis (10) 10
patient outcomes (10) 10
recommendations (10) 10
antineoplastic combined chemotherapy protocols - administration & dosage (9) 9
biomarkers (9) 9
cancer patients (9) 9
drug administration schedule (9) 9
drug therapy (9) 9
feasibility studies (9) 9
genetic aspects (9) 9
genetics (9) 9
health aspects (9) 9
hospitals (9) 9
medical research (9) 9
medicine & public health (9) 9
breast neoplasms - metabolism (8) 8
camptothecin - analogs & derivatives (8) 8
combined modality therapy (8) 8
dense sequential chemotherapy (8) 8
gene amplification (8) 8
her2 (8) 8
mutation (8) 8
neoplasm metastasis (8) 8
neoplasms (8) 8
oncology, experimental (8) 8
pathology (8) 8
phase-ii (8) 8
tissue microarrays (8) 8
adenocarcinoma - drug therapy (7) 7
adjuvant treatment (7) 7
anthracyclines (7) 7
antimitotic agents (7) 7
antineoplastic agents (7) 7
breast neoplasms - genetics (7) 7
camptothecin - administration & dosage (7) 7
endothelial growth-factor (7) 7
epirubicin - administration & dosage (7) 7
expression (7) 7
greece (7) 7
human (7) 7
leucovorin (7) 7
oxaliplatin (7) 7
patients (7) 7
proportional hazards models (7) 7
risk factors (7) 7
taxoids - administration & dosage (7) 7
trial (7) 7
tumors (7) 7
1st-line treatment (6) 6
article (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


BMC Cancer, ISSN 1471-2407, 06/2012, Volume 12, Issue 1, pp. 271 - 271
Background: The aim was to compare two standard chemotherapy regimens combined with bevacizumab as first-line treatment in patients with metastatic colorectal... 
Irinotecan | Chemotherapy | Capecitabine | Angiogenic markers | Colorectal cancer | Bevacizumab | COLON-CANCER | OSTEOPONTIN | ONCOLOGY | NITRIC-OXIDE | ORAL FLUOROPYRIMIDINES | BICC-C | EXPRESSION | CARCINOMA | ENDOTHELIAL GROWTH-FACTOR | Osteopontin - blood | Leucovorin - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - administration & dosage | Neoplasm Metastasis | Antibodies, Monoclonal, Humanized - administration & dosage | Fluorouracil - administration & dosage | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Camptothecin - administration & dosage | Female | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Fluorouracil - analogs & derivatives | Deoxycytidine - administration & dosage | Treatment Outcome | Biomarkers - blood | Angiogenic Proteins - blood | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Colorectal Neoplasms - pathology | Neoplasm Staging | Deoxycytidine - analogs & derivatives | Care and treatment | Patient outcomes | Research | Comparative analysis | Cancer | Clinical trials | Leucovorin | Metastasis | Antineoplastic agents | Antimitotic agents | Cancer patients | Nitric oxide | Product development | Vascular endothelial growth factor | Growth factors
Journal Article
BMC Cancer, ISSN 1471-2407, 02/2013, Volume 13, Issue 1, pp. 49 - 49
Background: More than half of patients with KRAS-wild type advanced colorectal cancer (CRC) fail anti-EGFR monoclonal antibodies. We studied EGFR-axis... 
PI3K gene mutations | Biomarkers | EGFR ligands | BRAF | KRAS | Cetuximab | Epidermal growth factor receptor | 1ST-LINE TREATMENT | LEUCOVORIN | EPIREGULIN | STATISTICS | FLUOROURACIL | CHEMOTHERAPY | BREAST-CANCER | PANITUMUMAB | MUTATION STATUS | ONCOLOGY | Colorectal Neoplasms - genetics | Humans | Middle Aged | Glycoproteins - metabolism | Male | Antineoplastic Agents - therapeutic use | Epiregulin | Amphiregulin | RNA, Messenger - metabolism | Intercellular Signaling Peptides and Proteins - metabolism | Receptor, Epidermal Growth Factor - metabolism | Adenocarcinoma - metabolism | EGF Family of Proteins | DNA Mutational Analysis | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Biomarkers, Tumor - metabolism | Adult | Female | Adenocarcinoma - genetics | Retrospective Studies | Colorectal Neoplasms - metabolism | Genes, ras - genetics | Genetic Predisposition to Disease | Antibodies, Monoclonal, Humanized - therapeutic use | Epidermal Growth Factor - metabolism | Genotype | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Phosphatidylinositol 3-Kinase - genetics | Proto-Oncogene Proteins B-raf - genetics | Colorectal Neoplasms - secondary | Aged | Drugs | Adverse and side effects | Research | Drug therapy | Patient outcomes | Colorectal cancer | Medical research | Care and treatment | Genes | Metastasis | Antineoplastic agents | Formaldehyde | Antimitotic agents | Messenger RNA | Epidermal growth factor | Codon | Gene mutations | Analysis | Monoclonal antibodies | Medicine, Experimental | Genetic aspects | Biological markers | Health aspects
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 03/2018, Volume 71, Issue 11, pp. A2086 - A2086
Background Anthracyclines are the cornerstone of chemotherapy for breast cancer, but its use is limited by cardiotoxicity development, which has been linked... 
Chemotherapy | Breast cancer | Bioavailability | Anthracycline
Journal Article
Journal Article
Journal of Translational Medicine, ISSN 1479-5876, 10/2012, Volume 10, Issue 1, pp. 212 - 212
Journal Article
PLoS ONE, ISSN 1932-6203, 12/2018, Volume 13, Issue 12, p. e0207707
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 7/2012, Volume 134, Issue 1, pp. 353 - 362
In spite the close association of the triple-negative breast cancer immunophenotype with hereditary breast cancers and the BRCA1 pathway, there is a lack of... 
Oncology | Hereditary breast–ovarian cancer | BRCA1 | Genetic testing | Medicine & Public Health | Triple-negative breast cancer | Hereditary breast-ovarian cancer | GENOMIC REARRANGEMENTS | FOUNDER MUTATIONS | ESTROGEN-RECEPTOR | PACLITAXEL | EPIRUBICIN | ONCOLOGY | RANDOMIZED PHASE-III | GERMLINE MUTATIONS | DENSE SEQUENTIAL CHEMOTHERAPY | YOUNG-WOMEN | CMF | Carcinoma, Ductal, Breast - genetics | Receptors, Estrogen - metabolism | Carcinoma, Ductal, Breast - epidemiology | Genetic Testing | Prevalence | Hereditary Breast and Ovarian Cancer Syndrome - diagnosis | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Carcinoma, Lobular - epidemiology | Hereditary Breast and Ovarian Cancer Syndrome - metabolism | Patient Selection | Receptors, Progesterone - metabolism | Young Adult | Carcinoma, Lobular - genetics | DNA Mutational Analysis | Aged, 80 and over | Adult | Female | Carcinoma, Ductal, Breast - metabolism | Hereditary Breast and Ovarian Cancer Syndrome - genetics | Carcinoma, Lobular - diagnosis | Carcinoma, Ductal, Breast - diagnosis | BRCA1 Protein - genetics | Heterozygote | Aged | Carcinoma, Lobular - metabolism | Hereditary Breast and Ovarian Cancer Syndrome - epidemiology | Mutation | BRCA mutations | Oncology, Experimental | Breast cancer | Research | Toy industry | Genetic screening | Prevalence studies (Epidemiology) | Ovarian cancer | Analysis | DNA | Genetic aspects | Diagnosis | Cancer
Journal Article
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 08/2017, Volume 12, Issue 8, p. e0180489
Background-Aim To evaluate the prognostic role of elaborate molecular clusters encompassing cyclin D1, cyclin E1, p21, p27 and p53 in the context of various... 
OVEREXPRESSION | COOPERATIVE ONCOLOGY GROUP | PROGNOSTIC-FACTOR | EPIRUBICIN | RANDOMIZED PHASE-III | MULTIDISCIPLINARY SCIENCES | DENSE SEQUENTIAL CHEMOTHERAPY | INHIBITORS | P21 | P27(KIP1) | Immunohistochemistry | Prognosis | Cyclin-Dependent Kinase Inhibitor p27 - analysis | Humans | Middle Aged | Antineoplastic Agents - therapeutic use | Triple Negative Breast Neoplasms - drug therapy | Breast Neoplasms - drug therapy | Young Adult | Cyclin D1 - analysis | Tumor Suppressor Protein p53 - analysis | Cyclin-Dependent Kinase Inhibitor p21 - analysis | Breast - drug effects | Breast Neoplasms - pathology | Triple Negative Breast Neoplasms - diagnosis | Cyclin E - analysis | Survival Analysis | Triple Negative Breast Neoplasms - pathology | Adult | Female | Aged | Breast Neoplasms - diagnosis | Oncogene Proteins - analysis | Breast - pathology | Usage | Analysis | Cell cycle | Clinical trials | Breast cancer | Research | Health sciences | GTP-binding protein | Regulators | Laboratories | Molecular clusters | p53 Protein | Oncology | Paraffin | Cyclin D1 | Kinases | Tissues | Cancer therapies | Formaldehyde | Cell adhesion & migration | Proteins | Medical research | Cyclin-dependent kinases | Clustering | Medicine | Pathology | Cyclin-dependent kinase inhibitor p21 | Hospitals | Medical prognosis | Breast | Tumors | Cancer | Apoptosis
Journal Article
PLoS ONE, ISSN 1932-6203, 07/2018, Volume 13, Issue 7, p. e0200302
Several studies support an important role of angiogenesis in breast cancer growth and metastasis. The main objectives of the study were to investigate the... 
CLINICAL ONCOLOGY/COLLEGE | RECOMMENDATIONS | MULTIDISCIPLINARY SCIENCES | FACTOR RECEPTOR 2 | LYMPHANGIOGENESIS | FACTOR EXPRESSION | VEGF-C | TUMOR ANGIOGENESIS | CARCINOMA | AMERICAN SOCIETY | ENDOTHELIAL GROWTH-FACTOR | Neovascularization, Pathologic - mortality | Neovascularization, Pathologic - diagnosis | Prognosis | Humans | Middle Aged | Proportional Hazards Models | Vascular Endothelial Growth Factor Receptor-2 - metabolism | Vascular Endothelial Growth Factor A - metabolism | Vascular Endothelial Growth Factor Receptor-3 - metabolism | Breast - metabolism | Breast Neoplasms - metabolism | Young Adult | Breast Neoplasms - pathology | Vascular Endothelial Growth Factor C - metabolism | Adult | Breast Neoplasms - mortality | Female | Aged | Breast Neoplasms - diagnosis | Neovascularization, Pathologic - metabolism | Breast - pathology | Proteins | Immunohistochemistry | Care and treatment | Cancer patients | Chemotherapy | Patient outcomes | Breast cancer | Vascular endothelial growth factor | Cancer | Health sciences | Laboratories | C protein | Oncology | Paraffin | Kinases | Subgroups | Metastases | Angiogenesis | Signal transduction | Receptors | Epidermal growth factor | Paraffins | Medical research | Parameters | Statistical tests | Gene expression | Patients | ErbB-2 protein | Survival | Vascular endothelial growth factor receptors | Medicine | Pathology | Gene amplification | Hospitals | Anthracycline | Medical prognosis | Biomarkers | Breast | Tumors
Journal Article
BMC Medicine, ISSN 1741-7015, 01/2011, Volume 9, Issue 1, pp. 10 - 10
Background: Colon cancer is a public health problem worldwide. Adjuvant chemotherapy after surgical resection for stage III colon cancer has been shown to... 
1ST-LINE TREATMENT | PLUS LEUCOVORIN | 5-FLUOROURACIL | MEDICINE, GENERAL & INTERNAL | MULTICENTER | THERAPY | PERSPECTIVES | CAMPTOTHECINS | OXALIPLATIN | METASTATIC COLORECTAL-CANCER | FOLFIRI | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Colonic Neoplasms - drug therapy | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Dose-Response Relationship, Drug | Greece | Young Adult | Fluorouracil - therapeutic use | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Adult | Camptothecin - administration & dosage | Female | Leucovorin - therapeutic use | Chemotherapy, Adjuvant | Camptothecin - analogs & derivatives | Camptothecin - adverse effects | Camptothecin - therapeutic use | Kaplan-Meier Estimate | Treatment Outcome | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Colonic Neoplasms - pathology | Aged | Neoplasm Staging | Chemotherapy | Usage | Colon cancer | Patient outcomes | Leucovorin | Drug therapy, Combination | Drug therapy | Health aspects | Fluorouracil | Cancer | Medical imaging | Heart attacks | Statistical analysis | Mortality | Colorectal cancer | Clinical trials | Histology | Cancer therapies | Manuscripts | Medicine | Hospitals | Tomography | Clinical medicine | Acquisitions & mergers | Index Medicus
Journal Article